CERTIFICATE OF ANALYSIS – TECHNICAL DATA SHEET

Product name	C6, Human, clone WU 6-4		
Catalog number	HM2276		
Lot number	-	**Expiry date**	-
Volume	1 ml	**Amount**	100 µg
Formulation	0.2 µm filtered in PBS+0.1%BSA	**Concentration**	100 µg/ml
Host Species	Mouse IgG1	**Conjugate**	None
Endotoxin	<24 EU/mg	**Purification**	Protein G
Storage	4°C		

Application notes

	IHC-F	IHC-P	IF	FC	FS	IA	IP	W
Reference #								
Yes		●	●	●	●	●	●	●
No								
N.D.	●							

N.D.= Not Determined; IHC = Immuno histochemistry; F = Frozen sections; P = Paraffin sections; IF = Immuno Fluorescence; FC = Flow Cytometry; FS = Functional Studies; IA = Immuno Assays; IP = Immuno Precipitation; W = Western blot

Dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50. For functional studies, in vitro dilutions have to be optimized in user's experimental setting.

General Information

Description

The monoclonal antibody WU 6-4 recognizes C6, one of the components of the terminal complement complex (TCC), also known as the membrane attack complex (MAC). Proteolytic cleavage of C5 by C5 convertase generates C5b which initiates assembly of the C5b-9 MAC. This complex is assembled from five precursor molecules in the serum, finalized with the polymerization of C9 which accompanies insertion of the complex into the cell membrane causing cellular lysis. Polymorphonuclear leukocytes represent a major source of C6. The monoclonal antibody WU 6-4 recognizes native C6 but not C6 after incorporation into the TCC. Furthermore, WU 6-4 is capable of inhibiting C5b6 and TCC formation in the fluid phase and to a lesser extent, haemolysis. Haemolytic activity could be inhibited only when WU 6-4 was introduced before C5b6 formation.

Immunogen

Human C6.

Cross reactivity

Primate: Yes; Rat: Yes.

References

1. Würzner R et al; Inhibition of terminal complement complex formation and cell lysis by monoclonal antibodies. Complement and Inflammation 1991, *8*: 328
2. Würzner R et al; Functionally active complement proteins C6 and C7 detected in C6- or C7- deficient individuals. Clin and Exp Immunol 1991, *83*: 430
3. Würzner R et al; Blood dendritic cells carry terminal complement complexes on their cell surface as detected by new developed neoepitope-specific monoclonal antibodies. Immunology 1991, *174*:32
4. Orren A et al; Properties of a low molecular weight complement component C6 found in human subjects with subtotal C6 deficiency. Immunol 1992, *75*: 10
5. Würzner R et al; Importance of the third thrombospondin repeat of C6 for terminal complement complex assembly. Immunol 1995, *85*: 214
6. Würzner R et al. (1995): Molecular basis of subtotal complement C6 deficiency: a carboxyterminally truncated but functionally active C6. J of Clin Invest 1995, *95*: 1877

Storage&stability

Product should be stored at 4°C. Under recommended storage conditions, product is stable for at least one year.

Precautions For research use only. Not for use in or on humans or animals or for diagnostics. It is the responsibility of the user to comply with all local/state and federal rules in the use of this product. Hycult Biotech is not responsible for any patent infringements that might result from the use or derivation of this product.

We hereby certify that the above-stated information is correct and that this product has been successfully tested by the Quality Control Department. This product was released for sale according to the existing specifications. This document has been produced electronically and is valid without a signature.

Approved by Manager of QC	Date
Robbert Zwinkels	19/03/2018

Do you have any questions or comments regarding this product? Please contact us via support@hycultbiotech.com.